Intestinal Microbiota in Patients with Chronic Hepatitis C with and Without Cirrhosis Compared with Healthy Controls
Overview
Authors
Affiliations
Background & Aims: The importance of the intestinal microbiota for the onset and clinical course of many diseases, including liver diseases like non-alcoholic steatohepatitis and cirrhosis, is increasingly recognized. However, the role of intestinal microbiota in chronic hepatitis C virus (HCV) infection remains unclear.
Methods: In a cross-sectional approach, the intestinal microbiota of 95 patients chronically infected with HCV (n=57 without cirrhosis [NO-CIR]; n=38 with cirrhosis [CIR]) and 50 healthy controls (HC) without documented liver diseases was analysed.
Results: Alpha diversity, measured by number of phylotypes (S) and Shannon diversity index (H'), decreased significantly from HC to NO-CIR to CIR. S and H' correlated negatively with liver elastography. Analysis of similarities revealed highly statistically significant differences in the microbial communities between HC, NO-CIR and CIR (R=.090; P<1.0×10 ). Stratifying for HCV genotypes even increased the differences. In addition, we observed distinct patterns in the relative abundance of genera being either positive or negative correlated with diseases status.
Conclusions: This study shows that not only the stage of liver disease but also HCV infection is associated with a reduced alpha diversity and different microbial community patterns. These differences might be caused by direct interactions between HCV and the microbiota or indirect interactions facilitated by the immune system.
Hupa-Breier K, Schenk H, Campos-Murguia A, Wellhoner F, Heidrich B, Dywicki J Mol Metab. 2025; 93:102104.
PMID: 39855563 PMC: 11815970. DOI: 10.1016/j.molmet.2025.102104.
Liu Y, Chen Z, Li C, Sun T, Luo X, Jiang B BMC Gastroenterol. 2025; 25(1):16.
PMID: 39806278 PMC: 11727502. DOI: 10.1186/s12876-025-03589-5.
Midori Y, Nosaka T, Hiramatsu K, Akazawa Y, Tanaka T, Takahashi K Front Cell Infect Microbiol. 2024; 14:1371429.
PMID: 38650735 PMC: 11033736. DOI: 10.3389/fcimb.2024.1371429.
Shah Y, Ali H, Tiwari A, Guevara-Lazo D, Nombera-Aznaran N, Pinnam B World J Hepatol. 2024; 16(1):17-32.
PMID: 38313244 PMC: 10835490. DOI: 10.4254/wjh.v16.i1.17.
Liver cirrhosis and complications from the perspective of dysbiosis.
Nie G, Zhang H, Xie D, Yan J, Li X Front Med (Lausanne). 2024; 10:1320015.
PMID: 38293307 PMC: 10824916. DOI: 10.3389/fmed.2023.1320015.